Expression of Podocalyxin-like Protein is an Independent Prognostic Biomarker in Resected Esophageal and Gastric Adenocarcinoma

Overview

Journal BMC Clin Pathol

Publisher Biomed Central

Date 2016 Aug 2

PMID 27478410

Citations 23

Authors

David Borg

Charlotta Hedner

Bjorn Nodin

Anna Larsson

Anders Johnsson

Jakob Eberhard

Karin Jirstrom

Affiliations

Soon will be listed here.

Abstract

Background: Podocalyxin-like protein (PODXL) is a cell surface transmembrane glycoprotein, the expression of which has been associated with poor prognosis in a range of malignancies. The aim of this study was to investigate the impact of PODXL expression on survival in esophageal and gastric adenocarcinoma.

Methods: The study cohort consists of a consecutive series of 174 patients with esophageal (including the gastroesophageal junction) or gastric adenocarcinoma, surgically treated between 2006 and 2010 and not subjected to neoadjuvant treatment. Immunohistochemical expression of PODXL was assessed in tissue microarrays with cores from primary tumors, lymph node metastases, intestinal metaplasia and adjacent normal epithelium. Survival analyses were performed on patients with no distant metastases and no macroscopic residual tumor.

Results: In the majority of cases, expression of PODXL was significantly higher in cancer cells compared to normal epithelial cells and was significantly associated with lymph node metastases and high grade tumors. In esophageal adenocarcinoma, Kaplan-Meier analyses revealed that patients with PODXL negative tumors had a superior time to recurrence (TTR) and overall survival (OS) compared to patients with PODXL positive tumors. In gastric adenocarcinoma, patients with PODXL negative tumors had a superior TTR and a trend towards an improved OS. In esophageal and gastric adenocarcinoma combined, the prognostic significance of PODXL expression on TTR was confirmed in unadjusted Cox regression analysis (HR = 5.36, 95 % CI 1.68-17.06, p = 0.005) and remained significant in the adjusted model (HR = 3.39, 95 % CI 1.01-11.35, p = 0.048). Moreover, the impact of PODXL expression on OS was also confirmed in unadjusted analysis (HR = 2.52, 95 % CI 1.31-4.85, p = 0.006) and remained significant in the adjusted model (HR = 2.03, 95 % CI 1.04-3.98, p = 0.039).

Conclusions: In esophageal and gastric adenocarcinoma, PODXL expression is an independent prognostic biomarker for reduced time to recurrence and poor overall survival. This is the first report on the prognostic role of PODXL in esophageal adenocarcinoma and validates recent findings in gastric cancer.

Citing Articles

Towards the Identification of New Biomarkers in Saliva and Serum for Treatment Monitoring of Equine Gastric Ulcer Syndrome: A Liquid Proteomic Approach.

Munoz-Prieto A, Rubic I, Resetar Maslov D, Gonzalez-Sanchez J, Mrljak V, Ceron J Animals (Basel). 2024; 14(21).

PMID: 39518828 PMC: 11545413. DOI: 10.3390/ani14213105.

Keratan sulfate, an electrosensory neurosentient bioresponsive cell instructive glycosaminoglycan.

Melrose J Glycobiology. 2024; 34(3).

PMID: 38376199 PMC: 10987296. DOI: 10.1093/glycob/cwae014.

Transcriptome sequencing identifies prognostic genes involved in gastric adenocarcinoma.

Li M, Bai M, Wu Y, Yang S, Zheng L, Sun L Mol Cell Biochem. 2023; 478(12):2891-2906.

PMID: 36944795 DOI: 10.1007/s11010-023-04705-3.

Multifaceted role of RNA editing in promoting loss-of-function of PODXL in cancer.

Fu T, Chan T, Bahn J, Kim T, Rowat A, Xiao X iScience. 2022; 25(8):104836.

PMID: 35992085 PMC: 9382340. DOI: 10.1016/j.isci.2022.104836.

MiR-199a-5p-containing macrophage-derived extracellular vesicles inhibit SMARCA4 and alleviate atherosclerosis by reducing endothelial cell pyroptosis.

Liang W, Chen J, Zheng H, Lin A, Li J, Wu W Cell Biol Toxicol. 2022; 39(3):591-605.

PMID: 35930100 DOI: 10.1007/s10565-022-09732-2.

References

Vitureira N, Andres R, Perez-Martinez E, Martinez A, Bribian A, Blasi J . Podocalyxin is a novel polysialylated neural adhesion protein with multiple roles in neural development and synapse formation. PLoS One. 2010; 5(8):e12003. PMC: 2919383. DOI: 10.1371/journal.pone.0012003. View

Binder Z, Siu I, Eberhart C, Ap Rhys C, Bai R, Staedtke V . Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome. PLoS One. 2013; 8(10):e75945. PMC: 3797817. DOI: 10.1371/journal.pone.0075945. View

Kaprio T, Fermer C, Hagstrom J, Mustonen H, Bockelman C, Nilsson O . Podocalyxin is a marker of poor prognosis in colorectal cancer. BMC Cancer. 2014; 14:493. PMC: 4226963. DOI: 10.1186/1471-2407-14-493. View

LAUREN P . THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965; 64:31-49. DOI: 10.1111/apm.1965.64.1.31. View

Larsson A, Fridberg M, Gaber A, Nodin B, Leveen P, Jonsson G . Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer. BMC Cancer. 2012; 12:282. PMC: 3492217. DOI: 10.1186/1471-2407-12-282. View

Hedner C, Tran L, Borg D, Nodin B, Jirstrom K, Eberhard J . Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis. Histopathology. 2015; 68(2):230-40. DOI: 10.1111/his.12744. View

Horvat R, Hovorka A, Dekan G, Poczewski H, Kerjaschki D . Endothelial cell membranes contain podocalyxin--the major sialoprotein of visceral glomerular epithelial cells. J Cell Biol. 1986; 102(2):484-91. PMC: 2114082. DOI: 10.1083/jcb.102.2.484. View

Hedner C, Borg D, Nodin B, Karnevi E, Jirstrom K, Eberhard J . Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma. PLoS One. 2016; 11(2):e0148101. PMC: 4742525. DOI: 10.1371/journal.pone.0148101. View

Larsson A, Johansson M, Wangefjord S, Gaber A, Nodin B, Kucharzewska P . Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer. 2011; 105(5):666-72. PMC: 3188928. DOI: 10.1038/bjc.2011.295. View

10.

Edgren G, Adami H, Weiderpass E, Weiderpass Vainio E, Nyren O . A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 2012; 62(10):1406-14. DOI: 10.1136/gutjnl-2012-302412. View

11.

Carr J, Zafar S, Saba N, Khuri F, El-Rayes B . Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. J Gastrointest Cancer. 2013; 44(2):143-51. DOI: 10.1007/s12029-013-9480-z. View

12.

Heby M, Elebro J, Nodin B, Jirstrom K, Eberhard J . Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma. BMC Clin Pathol. 2015; 15:10. PMC: 4449563. DOI: 10.1186/s12907-015-0009-1. View

13.

Flores-Tellez T, Lopez T, Vasquez Garzon V, Villa-Trevino S . Co-Expression of Ezrin-CLIC5-Podocalyxin Is Associated with Migration and Invasiveness in Hepatocellular Carcinoma. PLoS One. 2015; 10(7):e0131605. PMC: 4489913. DOI: 10.1371/journal.pone.0131605. View

14.

Huang Z, Huang Y, He H, Ni J . Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling. Mol Med Rep. 2015; 12(3):3916-3922. DOI: 10.3892/mmr.2015.3859. View

15.

Lin C, Sun M, Wu H . Podocalyxin-like 1 is associated with tumor aggressiveness and metastatic gene expression in human oral squamous cell carcinoma. Int J Oncol. 2014; 45(2):710-8. DOI: 10.3892/ijo.2014.2427. View

16.

Laitinen A, Bockelman C, Hagstrom J, Kokkola A, Fermer C, Nilsson O . Podocalyxin as a Prognostic Marker in Gastric Cancer. PLoS One. 2015; 10(12):e0145079. PMC: 4682935. DOI: 10.1371/journal.pone.0145079. View

17.

Fuccio L, Eusebi L, Bazzoli F . Gastric cancer, Helicobacter pylori infection and other risk factors. World J Gastrointest Oncol. 2010; 2(9):342-7. PMC: 2999139. DOI: 10.4251/wjgo.v2.i9.342. View

18.

Snyder K, Hughes M, Hedberg B, Brandon J, Hernaez D, Bergqvist P . Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy. Breast Cancer Res. 2015; 17:46. PMC: 4423095. DOI: 10.1186/s13058-015-0562-7. View

19.

Fristedt R, Gaber A, Hedner C, Nodin B, Uhlen M, Eberhard J . Expression and prognostic significance of the polymeric immunoglobulin receptor in esophageal and gastric adenocarcinoma. J Transl Med. 2014; 12:83. PMC: 4021601. DOI: 10.1186/1479-5876-12-83. View

20.

Larsson A, Nodin B, Syk I, Palmquist I, Uhlen M, Eberhard J . Podocalyxin-like protein expression in primary colorectal cancer and synchronous lymph node metastases. Diagn Pathol. 2013; 8:109. PMC: 3751142. DOI: 10.1186/1746-1596-8-109. View